<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Biogen Inc. (NASDAQ:BIIB) shares came under pressure Friday after the Food and Drug Administration called for an investigation into the approval of the company’s Alzheimer’s treatment Aduhelm. What Happened: In a letter disclosed publicly, FDA Acting Commissioner Janet Woodcock requested the office of the inspector general at the Department of Health and Human Services review and assess the interactions between representatives of Biogen and the FDA in the run up to the approval of the biologic license application for Aduhelm.
...read full article on Benzinga
